Patents by Inventor Daniela Angst
Daniela Angst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260132113Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: October 17, 2025Publication date: May 14, 2026Inventors: Daniela Angst, François Gessier, Anna Vulpetti
-
Publication number: 20260055085Abstract: The disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.Type: ApplicationFiled: March 26, 2025Publication date: February 26, 2026Inventors: Daniela ANGST, Philippe Bolduc, Matthew William Carson, Atwood Kim CHEUNG, Véronique Darsigny, Xiang GAO, Viktor HORNAK, Keith JENDZA, Rajesh KARKI, Ajay Kumar LAL, Gang LIU, Justin Yik Ching MAO, Jeffrey M. McKENNA, Erik MEREDITH, Muneto MOGI, Vivek RAUNIYAR, Liansheng SU, Ritesh TICHKULE, Shuangxi WANG, Chun ZHANG, Liang ZHAO, Rui ZHENG
-
Publication number: 20250268895Abstract: This application relates to various anhydrous crystalline forms N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, as well as compositions, method of making and methods of using the same. These crystalline forms are useful in the treatment of diseases and disorders which are typically ameliorated by the inhibition of BTK. Such diseases and disorders may include inflammatory and autoimmune disorders and pulmonary and respiratory tract inflammation.Type: ApplicationFiled: May 20, 2020Publication date: August 28, 2025Inventors: Daniela ANGST, Andreas KORDIKOWSKI
-
Patent number: 12129246Abstract: The disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.Type: GrantFiled: February 28, 2024Date of Patent: October 29, 2024Assignee: Novartis AGInventors: Daniela Angst, Philippe Bolduc, Matthew William Carson, Atwood Kim Cheung, Véronique Darsigny, Xiang Gao, Viktor Hornak, Keith Jendza, Rajesh Karki, Ajay Kumar Lal, Gang Liu, Justin Yik Ching Mao, Jeffrey M. McKenna, Erik Meredith, Muneto Mogi, Vivek Rauniyar, Liansheng Su, Ritesh Tichkule, Shuangxi Wang, Chun Zhang, Liang Zhao, Rui Zheng
-
Publication number: 20240336598Abstract: The disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.Type: ApplicationFiled: February 28, 2024Publication date: October 10, 2024Inventors: Daniela ANGST, Philippe Bolduc, Matthew William Carson, Atwood Kim CHEUNG, Véronique Darsigny, Xiang GAO, Viktor HORNAK, Keith JENDZA, Rajesh KARKI, Ajay Kumar LAL, Gang LIU, Justin Yik Ching MAO, Jeffrey M. McKENNA, Erik MEREDITH, Muneto MOGI, Vivek RAUNIYAR, Liansheng SU, Ritesh TICHKULE, Shuangxi WANG, Chun ZHANG, Liang ZHAO, Rui ZHENG
-
Publication number: 20230312483Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: May 1, 2023Publication date: October 5, 2023Inventors: Daniela ANGST, François GESSIER, Anna VULPETTI
-
Patent number: 11673868Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: GrantFiled: October 22, 2021Date of Patent: June 13, 2023Assignee: Novartis AGInventors: Daniela Angst, François Gessier, Anna Vulpetti
-
Publication number: 20220041561Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammartory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancer e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: October 22, 2021Publication date: February 10, 2022Inventors: Daniela ANGST, François GESSIER, Anna VULPETTI
-
Patent number: 11180460Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: GrantFiled: September 16, 2019Date of Patent: November 23, 2021Assignee: Novartis AGInventors: Daniela Angst, Francois Gessier, Anna Vulpetti
-
Publication number: 20200010426Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: September 16, 2019Publication date: January 9, 2020Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
-
Patent number: 10457647Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: GrantFiled: May 8, 2018Date of Patent: October 29, 2019Assignee: Novartis AGInventors: Daniela Angst, Francois Gessier, Anna Vulpetti
-
Publication number: 20180251432Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: May 8, 2018Publication date: September 6, 2018Inventors: Daniela ANGST, Francois GESSIER, Anna VULPETTI
-
Publication number: 20180140602Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.Type: ApplicationFiled: April 7, 2016Publication date: May 24, 2018Inventors: Daniela Angst, John Byrd, Jason Dubovsky, Joseph A. Fraietta, Francois Gessier, Saar Gill, Amy Johnson, Carl H. June, Marcela Maus, Natarajan Muthusamy, David L. Porter, Marco Ruella, Anna Vulpetti, Mariusz Wasik
-
Patent number: 9512084Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: GrantFiled: November 13, 2014Date of Patent: December 6, 2016Assignee: Novartis AGInventors: Daniela Angst, François Gessier, Anna Vulpetti
-
Publication number: 20160235746Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: April 21, 2016Publication date: August 18, 2016Applicant: NOVARTIS AGInventors: Daniela Angst, François Gessier, Anna Vulpetti
-
Publication number: 20150152068Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.Type: ApplicationFiled: November 13, 2014Publication date: June 4, 2015Applicant: NOVARTIS AGInventors: Daniela ANGST, François GESSIER, Anna VULPETTI
-
Patent number: 8791100Abstract: The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.Type: GrantFiled: January 28, 2011Date of Patent: July 29, 2014Assignee: Novartis AGInventors: Daniela Angst, Birgit Bollbuck, Philipp Janser, Jean Quancard, Nikolaus Johannes Stiefl
-
Publication number: 20110190258Abstract: The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.Type: ApplicationFiled: January 28, 2011Publication date: August 4, 2011Applicant: NOVARTIS AGInventors: Daniela ANGST, Birgit BOLLBUCK, Philipp JANSER, Jean QUANCARD, Nikolaus Johannes STIEFL
-
Publication number: 20100168079Abstract: The present invention relates to biaryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.Type: ApplicationFiled: December 21, 2009Publication date: July 1, 2010Inventors: Daniela Angst, Birgit Bollbuck, Philipp Janser, Jean Quancard
